Per una progettazione partecipata dei gruppi di lettura: prove pratiche al Centro Gender*MoRe

Il neonato Centro di documentazione Gender*MoRe ha come primarie attività quelle di documentare la letteratura scientifica incentrata sui temi delle disparità di genere nel mondo accademico e di promuovere la gender equality con iniziative di sensibilizzazione dedicate. In questa breve relazione vengono illustrati gli step progettuali che mirano alla creazione partecipata di un gruppo di lettura aperto agli utenti universitari e alla cittadinanza

Opposite Response to Vitamin K Antagonists: A Report of Two Cases and Systematic Review of Literature

Vitamin K antagonists (VKAs) are used in the prophylaxis and treatment of thromboembolic disorders. Despite a high efficacy, their narrow therapeutic window and high response variability hamper their management. Several patients experience fluctuations in dose–response and are at increased risk of over- or under-anticoagulation. Therefore, it is essential to monitor the prothrombin time/international normalized ratio to determine the so-called stable dose and to adjust the dosage accordingly. Three polymorphisms, CYP2C9∗2, CYP2C9∗3 and VKORC1-1639G>A, are associated with increased sensitivity to VKAs. Other polymorphisms are associated with a request for a higher dose and VKA resistance. We described the clinical cases of two patients who were referred to the Clinical Pharmacology and Pharmacogenetics Unit of the University Hospital of Salerno for pharmacological counseling. One of them showed hypersensitivity and the other one was resistant to VKAs. A systematic review was performed to identify randomized clinical trials investigating the impact of pharmacogenetic testing on increased sensitivity and resistance to VKAs. Although international guidelines are available and information on the genotype-guided dosing approach has been included in VKA drug labels, VKA pharmacogenetic testing is not commonly required. The clinical cases and the results of the systematically reviewed RCTs demonstrate that the pharmacogenetic-based VKA dosing model represents a valuable resource for reducing VKA-associated adverse events

Evaluation of the Photocatalytic Activity of a Cordierite-Honeycomb-Supported TiO2 Film with a Liquid–Solid Photoreactor

Anatase nanoparticles in suspension have demonstrated high photoactivity that can be exploited for pollutant removal in water phases. The main drawback of this system is the difficulty of recovering (and eventually reusing) the nanoparticles after their use, and the possible interference of inorganic salts (e.g., sulfates) that can reduce the performance of the photocatalyst. The present work describes the development of a cordierite-honeycomb-supported TiO2 film to eliminate the problems of catalyst recovery. The catalyst was then tested against phenol in the presence of increasing concentrations of sulfates in a specially developed recirculating modular photoreactor, able to accommodate the supported catalyst and scalable for application at industrial level. The effect of SO42− was evaluated at different concentrations, showing a slight deactivation only at very high sulfate concentration (≥3 g L−1). Lastly, in the framework of the EU project Project Ô, the catalyst was tested in the treatment of real wastewater from a textile company containing a relevant concentration of sulfates, highlighting the stability of the photocatalyst

Concomitant Administration of Capecitabine and Folate Supplements: Need to Encourage Medication Reconciliation

Hand-Foot syndrome (HFS) and diarrhoea are dose-limiting Adverse Drug Reactions (ADRs) of capecitabine-based chemotherapy. Four polymorphisms in the dihydropyrimidine dehydrogenase (DPYD) gene, encoding the DPD enzyme responsible for the metabolism of fluoropyrimidines, such as capecitabine, are strongly associated with severe ADRs, and their screening should be performed before starting treatment. Moreover, capecitabine-related toxicity may worsen due to drug-drug and drug-supplement interactions. Here we investigated factors responsible for severe HFS and diarrhoea presented by two patients, non-carriers of the recommended DPYD single nucleotide polymorphisms (SNPs) but carriers of other genetic variants suggested to increase the risk of capecitabine-related ADRs. Through careful therapy recognition, we demonstrated that, unbeknownst to the oncologists, the patients were taking folic acid during the treatment with capecitabine at a dosage higher than 2000 mg/m(2), which is the maximum tolerated dose when folate is administered. To resolve the ADRs, the therapy had to be drastically changed. In one case, dose reduction of capecitabine and discontinuation of lipid-lowering agents were carried out. In the other case, discontinuation of capecitabine and folic acid and capecitabine re-administration were performed after a month. Genetic and environmental factors should be considered good predictors of severe capecitabine-related toxicity. Medication reconciliation should be encouraged to avoid the harmful consequences of inappropriate treatments

Epicardial adipose tissue has an increased thickness and is a source of inflammatory mediators in patients with calcific aortic stenosis

No abstrac